Protocol Ledger

NCT06881836 · Phase II · COMPLETED

A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease

Interventional Phase II clinical trial protocol NCT06881836 sponsored by Ono Pharmaceutical Co in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-04-24 Enrollment: 260 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06881836
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)260 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06881836
Protocol FieldVerified Registry Value
NCT IdentifierNCT06881836
Consolidated Lead SponsorOno Pharmaceutical Co
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment260 participants (ACTUAL)
Registered Start Date2025-04-24
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06881836
Hospital Research SiteLocationSite Profile
Stanford Health Care and Stanford Cancer InstituteStanford, CAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI